检索结果-南通市图书馆

Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives

World Journal of Gastroenterology 2019年第38期25卷 5773-5788页

作者： Antonio Pellino Erika Riello Floriana Nappo Stefano Brignola Sabina Murgioni Selma Ahcene Djaballah Sara Lonardi vittorina zagonel Massimo Rugge Fotios Loupakis Matteo Fassan Department of Oncology Veneto Institute of Oncology IOV-IRCCSPadua 35100Italy Department of Surgery Oncology and GastroenterologyUniversity of PaduaPadua 35100Italy Surgical Pathology&Cytopathology Unit Department of MedicineUniversity of PaduaPadua 35100Italy Veneto Cancer Registry Padua 35100Italy

Gastric cancer(GC)represents a leading cause of cancer related morbidity and mortality worldwide accounting for more than 1 million of newly diagnosed cases and thousands of deaths every *** the last decade,the development of targeted therapies and the optimization of already available chemotherapeutic drugs has expanded the available treatment options for advanced GC and granted better survival expectations to the *** the same time,global efforts have been undertaken to investigate in detail the genomic and epigenomic heterogeneity of this disease,resulting in the identification of new specific and sensitive predictive and prognostic biomarkers and in innovative molecular classifications based on gene expression ***,several randomized studies aimed at exploring new innovative agents,such as immune checkpoint inhibitors,failed to demonstrate clinically meaningful survival ***,it is essential to further improve the molecular characterization of GC subgroups in order to provide researchers and medical oncologists with new tools for patients’selection and stratification in future clinical development programs and subsequent *** aim of the present manuscript is to provide a global overview of the recent molecular classifications from The Cancer Genome Atlas and the Asian Cancer Research Group and to present key promising developments in the field of immunotherapy and targeted therapies in metastatic GC.

关键词： Gastric cancer Personalized medicine Predictive biomarkers Molecular diagnostic The Cancer Genome Atlas Asian Cancer Research Group

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Gliomatosis cerebri: a monocentric real-life experience

引用

Journal of Cancer Metastasis and Treatment 2021年第1期7卷 404-411页

作者： Luisa Bellu Mario Caccese Giulia Cerretti Franco Berti Fabio Busato Alessandro Parisi Marta Padovan vittorina zagonel Giuseppe Lombardi Radiotherapy Unit-Imaging and Medical Physics Department Veneto Institute of Oncology-IOV-IRCCSPadova 6435128Italy Department of Oncology Oncology 1Veneto Institute of Oncology-IOV-IRCCSPadova 6435128Italy

Aim:Gliomatosis cerebri(GC)is defined as a rare pattern of growth of diffuse gliomas involving three or more cerebral *** its rarity,it is difficult to define prognostic factors and standard of *** retrospectively analyzed patients(PT)with GC from a single institution with the aim of identifying the main prognostic factors and to assess optimal ***:Medical records were reviewed of patients≥18 years with a histological and/or radiological diagnosis of GC(with no contrast enhancement)occurring between 2006 and *** progression free survival(PFS)and overall survival(OS)were calculated by the Kaplan-Meier ***:We analyzed 33 PT,22 males and 11 females;Eastern Cooperative Oncology Group(ECOG)performance status(PS)was 0-1 in 21 of the ***-two PT underwent biopsy:16 were astrocytomas and 6 oligodendrogliomas.O6-methylguanin-DNA-methyltransferase(MGMT)was detected in 14 cases,and it was methylated in eight *** dehydrogenase 1(IDH1)was analyzed in 16 PT,and it had mutated in 10 of *** PT(27%)were treated with radiation therapy(RT)plus concurrent temozolomide(TMZ),22 PT(67%)received TMZ alone,and 2 PT(6%)underwent RT *** reported“complete response”in 1 patient(3%),partial response in 9 PT(27%),and stable disease in 15 PT(45%),while 8 PT(25%)had a progressive *** all PT,PFS and OS were 19.1 and 30.7 months,*** ECOG PS 0-1 and≥2,PFS was 34.6 months vs.3.4 months(P<0.0001)and OS was 42 months vs.8.9 months(P<0.0001),*** MGMT was associated with longer PFS(41.6 months vs.8.9 months,P=0.05)and OS(52.7 months vs.14.6 months,P=0.009);PFS for IDH1 mutation and IDH wild-type was 52.7 months vs.8.9 months(P=0.006)and OS was 52.7 months vs.41.7 months(P=0.02),*** significant difference was detected as regards *** regard to histological subtype,OS was 42.0 months vs.52.7 months(P=0.8)and PFS was 41.6 months vs.28.6 months(P=0.7)for astrocyt

关键词： Low-grade gliomas gliomatosis cerebri temozolomide IDH radiotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma

引用

World Journal of Gastroenterology 2017年第13期23卷 2448-2452页

作者： Lorenza Rimassa Maria Reig Giovanni Abbadessa Markus Peck-Radosavljevic William Harris vittorina zagonel Davide Pastorelli Elena Rota Caremoli Camillo Porta Nevena Damjanov Hitendra Patel Bruno Daniele Maria Lamar Brian Schwartz Terri Goldberg Armando Santoro Jordi Bruix Medical Oncology and Hematology Unit Humanitas Cancer CenterHumanitas Clinical and Research Center Barcelona Clinic Liver Cancer Group Liver UnitHospital ClinicUniversity of BarcelonaIDIBAPSCIBERehd Clinical Development Ar QuleInc Department of Gastroenterology HepatologyEndrocrinologyand NephrologyKlinikum Klagenfurt am Worthersee Department of Medicine Oncology DivisionUniversity of Washington School of Medicine Department of Clinical and Experimental Oncology Medical Oncology 1Veneto Institute of Oncology-IRCCS Department of Oncology Santa Maria del Prato Hospital Department of Oncology Papa Giovanni XXIII Hospital Department of Oncology Fondazione IRCCS Policlinico San Matteo Division of Gastrointestinal Oncology Abramson Cancer Center of the University of Pennsylvania Department of Medicine The University of Arizona Cancer Center Department of Oncology G.Rummo Hospital Clinical Development Daiichi Sankyo Medical Oncology and Hematology Unit Humanitas Cancer CenterHumanitas Clinical and Research CenterHumanitas University

Tumor biopsies may help to reliably distinguish hepatocellular carcinoma(HCC) from other tumors, mostly cholangiocarcinoma as well as to identify the patient populations who most benefit from target-driven HCC treatments, in order to improve the success rate of experimental therapies. Clarifying tumor biology may also lead to identify biomarkers with prognostic role and/or enabling to predict response or resistance to therapies. Recently, clinical trials have more efficiently included biomarker endpoints and increasingly collected tumor tissue from enrolled patients. Due to their frail status and sometimes fast-progressing disease, the performance status of patients with HCC progressing on first-line therapy can deteriorate quickly, preventing their enrollment in clinical trials. However, the challenge of identifying the proper patient at the proper time can be overcome by periodic inter-department meetings involving the key specialists taking care of HCC patients, and solid networks between research centers and referring institutions. An early planned biopsy would also facilitate timely inclusion of patients in biology-driven clinical trials. Ultimately, institution of multidisciplinary teams can optimize treatment choice, biopsy timing, and quick enrollment of patients in clinical trials, before their performance status deteriorates.

关键词： Liver neoplasms Biopsy Biomarkers Clinical trial Tumor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatocellular carcinoma in elderly patients:a concise reviewon systemic therapy with sorafenib

引用

Hepatoma Research 2015年第1期1卷 58-62页

作者： Lombardi Giuseppe Vitale Alessandro Sara Lonardi Bellu Luisa Pambuku Ardi Marsico Valentina Crivellari Gino Aliberti Camillo Cillo Umberto zagonel vittorina Department of Clinical and Experimental Oncology Medical Oncology 1Veneto Institute of Oncology-IRCCS35128 PaduaItaly Department of Surgery Oncology and GastroenterologyUniversity of Padua35122 PaduaItaly Interventional Oncology Unit Veneto Institute of Oncology-IRCCS35128 PaduaItaly

The treatment of hepatocellular carcinoma(HCC)in elderly patients is *** particular,the effi cacy and safety of sorafenib as a systemic treatment in these patients is still under *** performed a concise review of sorafenib therapy in this ***,it is important to make any decisions on treatment for elderly patients with HCC through a multidisciplinary team that includes experts in the liver *** with good clinical conditions should be treated with sorafenib.

关键词： Hepatocellular carcinoma sorafenib treatment chemotherapy elderly patients

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：